Canine leishmaniosis, caused by Leishmania infantum, is a vector-borne disease. The immune response in infected dogs ...

Tata Communications integrates TGN-IA2 cable, boosting intra-Asia connectivity and extending global reach with faster, scalable, low-latency infrastructure.

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B for the German biotech.

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression ...

WILMINGTON, Del., June 03, 2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025 ...

Cellular therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies (BsAbs), have revolutionized the treatment of various B-cell non-Hodgkin lymphomas. A number of agents ...

Zymeworks Inc. announced that their bispecific antibody, zanidatamab, has received conditional approval from China's National Medical Products Administration (NMPA) for treating previously treated ...

ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset By Gabrielle Masson Jun 1, 2025 3:36pm Bicara Therapeutics ASCO 2025 Merus ASCO ...

A Phase 1/2 clinical study of PD-1/IL-2 α-bia s bispecific antibody fusion protein (IBI363) in the treatment of advanced "cold" tumor subtypes (acral and mucosal) malignant melanoma. The data ...